AstraZeneca (AZN) U.S. Covid-19 Vaccine Trial Data Is Now Under Review By Independent Review Board- NIH Director Collins via Reuters
- Dow hits milestone, S&P breaks record high on tech rally
- Thermo Fisher Scientific (TMO) to Acquire PPD, Inc. (PPD) for $47.50/sh, $17.4 Billion
- U.S. retail sales post largest gain in 10 months; weekly jobless claims fall
- Dell (DELL) Gains on Spin-Off of its 81% Stake in VMware (VMW), Analysts Bulled-Up as It Could Unlock $20 Per Share of Value for DELL
- The Stock Market is Almost 'Completely Broken' - Einhorn
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
AstraZeneca (NASDAQ: AZN) U.S. Covid-19 Vaccine Trial Data Is Now Under Review By Independent Review Board- NIH Director Collins via Reuters
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Denmark to Drop Use of AstraZeneca (AZN) Vaccine From Program - Bloomberg
- Merck (MRK) to Discontinue Development of MK-7110 for COVID-19
- J&J (JNJ) Adverse Event Pattern Looks Similar to Astra (AZN) Shot, Official Says
Create E-mail Alert Related CategoriesFDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!